Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising therapeutic option for managing DKD, with evidence from clinical trials such as CREDENCE and DAPA-CKD demonstrating their substantial renal benefits. The gene discussed is SLC5A2; the disease is chronic kidney disease.